• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Drug Delivery Technologies - Current Market Dynamics, Future Market Opportunities and Lifecycle Strategies - Product Image

Drug Delivery Technologies - Current Market Dynamics, Future Market Opportunities and Lifecycle Strategies

  • ID: 659694
  • September 2008
  • Region: Global
  • 283 Pages
  • Arrowhead Publishers

FEATURED COMPANIES

  • 3m Pharmaceuticals
  • Bioject
  • Depomed
  • Enzon
  • Macrochem
  • Noven
  • MORE

Overview

The drug delivery industry has in recent years become a key partner for pharmaceutical companies in their efforts to maximize the patent lives of successful products. Drug delivery companies not only stand to benefit from patent expiry by providing their reformulation services to pharmaceutical companies, but also by producing their own versions of branded products with improved delivery mechanisms. Thus, post-patent expiry sales can be switched from the ethical manufacturer to the drug delivery sector.

Drug Delivery Technologies: Current Market Dynamics, Future Market Opportunities and Lifecycle Strategies is an up-to-date guide that assesses the current state of the drug delivery industry and its application to both the pharmaceutical and biotech industries. While the sector is still dominated by oral technologies, drug delivery systems have expanded to include more novel devices such as needleless injectables, PEGylation platforms and microelectromechanical devices. These technological advances extend the duration of a drug's action, increase delivery to target sites, reduce delivery to unwanted sites, and maximize drug absorption.

The expanding market READ MORE >

FEATURED COMPANIES

  • 3m Pharmaceuticals
  • Bioject
  • Depomed
  • Enzon
  • Macrochem
  • Noven
  • MORE

1 INTRODUCING THE FIELD OF DRUG DELIVERY
1.1 THE VALUE OF DRUG DELIVERY SYSTEMS
1.2 DRUG DELIVERY AND PRODUCT DIFFERENTIATION
1.3 DRUG DELIVERY AND PATENT EXTENSION
1.4 THE OPTIMAL TIME FOR REFORMULATION
1.5 OPTIMIZING R&D RETURNS THROUGH DRUG DELIVERY
1.6 OPPORTUNITIES AND THREATS TO THE DRUG DELIVERY SECTOR
1.6.1 Opportunities for Growth in the Drug Delivery Sector
1.6.2 Threats to Additional Growth in the Drug Delivery Sector
1.7 BUSINESS MODELS OF DRUG DELIVERY COMPANIES

2 AN OVERVIEW OF DRUG DELIVERY TECHNOLOGIES
2.1 ORAL DRUG DELIVERY
2.1.1 Controlled Release
2.1.2 Sustained Release
2.1.3 Chronomodulation
2.1.4 Rapid Dissolving and Taste-masking Tablets
2.1.5 Macromolecular Drug Delivery
2.1.6 Microemulsion
2.1.7 Pulsatile Drug Delivery
2.2 INHALABLE DRUG DELIVERY
2.2.1 Nebulizers
2.2.2 Metered Dose Inhalers (MDIs)
2.2.3 Dry Powder Inhalers (DPIs)
2.2.4 Limitations of Pulmonary Delivery Systems for Systemic Delivery
2.2.5 Aqueous Systems
2.2.6 Crystallization Technology
2.2.7 Electrohydrodynamic (EHD) Aerosol Delivery
2.2.8 Liposomal Systems
2.3 INJECTABLE DRUG DELIVERY
2.3.1 Sustained Release Injectable Systems
2.3.2 Liposomal Systems
2.3.3 Needleless Systems
2.3.4 New Injectable Technologies
2.4 TRANSMUCOSAL DRUG DELIVERY
2.4.1 Buccal Delivery
2.4.2 Nasal
2.4.3 Rectal
2.4.4 Vaginal
2.5 TRANSDERMAL DRUG DELIVERY
2.5.1 Passive Formulations
2.5.2 Active Formulations
2.6 NICHE TECHNOLOGIES
2.6.1 Topical Systems
2.6.2 Gene Delivery
2.6.3 Implantable Systems
2.6.4 Drug Delivery Microchips
2.6.5 Nanotechnology

3 OVERVIEW OF GLOBAL DRUG DELIVERY MARKET
3.1 IMPORTANCE OF DRUG DELIVERY
3.2 GLOBAL DRUG DELIVERY MARKET BY GEOGRAPHIC AREA
3.3 GLOBAL DRUG DELIVERY MARKET BY SEGMENT
3.4 GLOBAL DRUG DELIVERY MARKET FORECASTS

4 DRUG DELIVERY MARKET ANALYSIS
4.1 KEY MARKET SEGMENTS
4.1.1 Oral Drug Delivery
4.1.1.1 Sales of Products Utilizing Oral Drug Delivery Technology
4.1.1.2 Key Therapeutic Areas for Oral Drug Delivery
4.1.1.3 Key Oral Drug Delivery Products Impacting Global Market
4.1.1.4 The Outlook for Oral Drug Delivery Technology
4.1.1.5 Drivers and Restraints
4.1.2 Inhalable Drug Delivery
4.1.2.1 Sales of Products Utilizing Inhalable Drug Delivery Technology
4.1.2.2 Key Therapeutic Areas for Inhalable Drug Delivery
4.1.2.3 Key Inhalable Drug Delivery Products Impacting Global Market
4.1.2.4 The Outlook for Inhalable Drug Delivery Technology
4.1.2.5 Drivers and Restraints
4.1.3 Injectable Drug Delivery
4.1.3.1 Sales of Products Utilizing Injectable Drug Delivery Technology
4.1.3.2 Key Therapeutic Areas for Injectable Drug Delivery
4.1.3.3 Key Injectable Drug Delivery Products Impacting Global Market
4.1.3.4 The Outlook for Injectable Drug Delivery Technology
4.1.3.5 Drivers and Restraints
4.1.4 Transmucosal Drug Delivery
4.1.4.1 Sales of Products Utilizing Transmucosal Drug Delivery Technology
4.1.4.2 Key Therapeutic Areas for Transmucosal Delivery
4.1.4.3 Key Transmucosal Drug Delivery Products Impacting Global Market
4.1.4.4 The Outlook for Transmucosal Drug Delivery Technology
4.1.4.5 Drivers and Restraints
4.1.5 Transdermal Drug Delivery
4.1.5.1 Sales of Products Utilizing Transdermal Drug Delivery Technology
4.1.5.2 Key Therapeutic Areas for Transdermal Drug Delivery
4.1.5.3 Key Transdermal Drug Delivery Products Impacting Global Market
4.1.5.4 The Outlook for Transdermal Drug Delivery Technology
4.1.5.5 Drivers and Restraints
4.1.6 Niche Drug Delivery Technologies
4.1.6.1 Sales of Products Utilizing Niche Drug Delivery Technologies
4.1.6.2 Key Niche Drug Delivery Technology Product Impacting Global Market
4.1.6.3 The Outlook for Niche Drug Delivery Technologies
4.1.6.4 Drivers and Restraints

5 EMERGING DRUG DELIVERY TECHNOLOGIES: ORAL DRUG DELIVERY
5.1 KEY PRODUCT PROFILES
5.2 KEY COMPANY INVOLVEMENT IN THE FIELD OF ORAL DRUG DELIVERY
5.2.1 ALZA
5.2.2 Biovail
5.2.3 Cardinal Health
5.2.4 Depomed
5.2.5 Emisphere
5.2.6 Ethypharm
5.2.7 Penwest

6 EMERGING DRUG DELIVERY TECHNOLOGIES: INHALABLE DRUG DELIVERY
6.1 KEY PRODUCT PROFILES
6.2 KEY COMPANY INVOLVEMENT IN THE FIELD OF INHALABLE DRUG DELIVERY
6.2.1 3M
6.2.2 Alkermes
6.2.3 Aradigm
6.2.4 Nektar
6.2.5 SkyePharma

7 EMERGING DRUG DELIVERY TECHNOLOGIES: INJECTABLE DRUG DELIVERY
7.1 KEY PRODUCT PROFILES
7.2 KEY COMPANY INVOLVEMENT IN THE FIELD OF INJECTABLE DRUG DELIVERY
7.2.1 Alkermes
7.2.2 ALZA
7.2.3 Enzon
7.2.4 Ethypharm
7.2.5 Macromed
7.2.6 Nektar
7.2.7 QLT

8 EMERGING DRUG DELIVERY TECHNOLOGIES: TRANSMUCOSAL DRUG DELIVERY
8.1 KEY PRODUCT PROFILES
8.2 KEY COMPANY INVOLVEMENT IN THE FIELD OF TRANSMUCOSAL DRUG DELIVERY
8.2.1 Generex
8.2.2 Nastech
8.2.3 Pherin

9 EMERGING DRUG DELIVERY TECHNOLOGIES: TRANSDERMAL DRUG DELIVERY
9.1 KEY PRODUCT PROFILES
9.2 KEY COMPANY INVOLVEMENT IN THE FIELD OF TRANSDERMAL DRUG DELIVERY
9.2.1 3M
9.2.2 Altea Therapeutics
9.2.3 ALZA
9.2.4 Aradigm
9.2.5 Noven

10 EMERGING DRUG DELIVERY TECHNOLOGIES: NICHE DRUG DELIVERY TECHNOLOGIES
10.1 KEY PRODUCT PROFILES
10.2 KEY COMPANY INVOLVEMENT IN NICHE DRUG DELIVERY TECHNOLOGIES
10.2.1 ALZA
10.2.2 Connetics (now Stiefel Laboratories)
10.2.3 Inovio
10.2.4 MacroChem
10.2.5 NexMed
10.2.6 pSivida
10.2.7 QLT
10.2.8 SkyePharma

11 KEY DRUG DELIVERY COMPANY PROFILES
11.1 3M PHARMACEUTICALS
11.2 ALKERMES
11.3 ALTEA THERAPEUTICS
11.4 ALZA (JOHNSON & JOHNSON)
11.5 ARADIGM
11.6 BIOJECT
11.7 BIOVAIL
11.8 CARDINAL HEALTH
11.9 CIMA LABS (CEPHALON)
11.10 CONNETICS (STIEFEL LABORATORIES INC.)
11.11 CYDEX PHARMACEUTICALS
11.12 DELSITE BIOTECHNOLOGIES (CARRINGTON LABORATORIES)
11.13 DEPOMED
11.14 DOR BIOPHARMA
11.15 DURECT
11.16 EMISPHERE
11.17 ENZON
11.18 ETHYPHARM
11.19 EURAND
11.20 GENEREX
11.21 INOVIO (FORMERLY GENETRONICS)
11.22 IVAX (PART OF TEVA)
11.23 MACROCHEM
11.24 MACROMED (NOW PROTHERICS)
11.25 NASTECH (NOW MDRNA)
11.26 NEKTAR
11.27 NEXMED
11.28 NOVEN
11.29 PSIVIDA
11.30 PENWEST
11.31 PHERIN PHARMACEUTICALS
11.32 QLT
11.33 SKYEPHARMA
11.34 WATSON PHARMACEUTICALS
11.35 ZOGENIX

Tables
TABLE 2.1 DRUGS SUITABLE OR UNSUITABLE FOR CONTROLLED RELEASE
TABLE 2.2 ADVANTAGES AND DISADVANTAGES OF TRANSDERMAL DELIVERY
TABLE 3.1 GLOBAL SALES OF DRUG DELIVERY SYSTEMS BY KEY SEGMENTS, 2007
TABLE 3.2 FORECAST GLOBAL SALES OF DRUG DELIVERY SYSTEMS BY SEGMENT, US$ BILLION
TABLE 4.1 KEY ORAL DRUG DELIVERY PRODUCTS, 2004-2007** ($ MN)
TABLE 4.2 LEADING ORAL DRUG DELIVERY COMPANIES 2007, KEY PRODUCTS AND SALES 2007 ($MN)
TABLE 4.3 KEY INHALABLE DRUG DELIVERY PRODUCTS, 2004-2007** ($ MN)
TABLE 4.4 KEY INJECTABLE DRUG DELIVERY PRODUCTS, 2004-2007** ($ MN)
TABLE 4.5 LEADING INJECTABLE DRUG DELIVERY COMPANIES 2007, KEY PRODUCTS AND SALES 2007 ($ MN)
TABLE 4.6 KEY TRANSMUCOSAL DRUG DELIVERY PRODUCTS, 2004-2007**
($ MN)
TABLE 4.7 KEY TRANSDERMAL DRUG DELIVERY PRODUCTS, 2004-2007#
($ MN)
TABLE 4.8 KEY TOPICAL DRUG DELIVERY PRODUCTS, 2007
TABLE 4.9 KEY NICHE DRUG DELIVERY PRODUCTS, 2004-2007 ($ MN)
TABLE 5.1 KEY ORAL DRUG DELIVERY R&D PIPELINE DRUGS, 2008
TABLE 6.1 KEY INHALABLE DRUG DELIVERY R&D PIPELINE DRUGS, 2008
TABLE 7.1 KEY INJECTABLE DRUG DELIVERY R&D PIPELINE DRUGS, 2008
TABLE 8.1 KEY TRANSMUCOSAL DRUG DELIVERY R&D PIPELINE DRUGS, 2008
TABLE 9.1 KEY TRANSDERMAL DRUG DELIVERY R&D PIPELINE DRUGS, 2008
TABLE 10.1 KEY TOPICAL DRUG DELIVERY R&D PIPELINE DRUGS, 2008
TABLE 10.2 KEY NICHE DRUG DELIVERY R&D PIPELINE DRUGS, 2008
TABLE 11.1 3M KEY FINANCIALS, 2003-2007 (US$MN)
TABLE 11.2 3M DRUG DELIVERY PORTFOLIO, 2008
TABLE 11.3 ALKERMES KEY FINANCIALS, 2003-2007 (US$MN)
TABLE 11.4 ALKERMES DRUG DELIVERY PORTFOLIO, 2008
TABLE 11.5 ALTEA THERAPEUTICS DRUG DELIVERY PORTFOLIO, 2008
TABLE 11.6 ALZA DRUG DELIVERY PORTFOLIO, 2008
TABLE 11.7 ARADIGM KEY FINANCIALS, 2003-2007 (US$MN)
TABLE 11.8 ARADIGM DRUG DELIVERY PORTFOLIO, 2008
TABLE 11.9 BIOJECT KEY FINANCIALS, 2003-2007 (US$MN)
TABLE 11.10 BIOJECT DRUG DELIVERY PORTFOLIO, 2008
TABLE 11.11 BIOVAIL KEY FINANCIALS, 2003-2007 (US$MN)
TABLE 11.12 BIOVAIL DRUG DELIVERY PORTFOLIO, 2008
TABLE 11.13 CARDINAL HEALTH KEY FINANCIALS, 2003-2007 (US$MN)
TABLE 11.14 CARDINAL HEALTH DRUG DELIVERY PORTFOLIO, 2008
TABLE 11.15 CEPHALON KEY FINANCIALS, 2003-2007 (US$MN)
TABLE 11.16 CIMA LABS DRUG DELIVERY PORTFOLIO, 2008
TABLE 11.17 CONNETICS KEY FINANCIALS, 2003-2007 (US$MN)
TABLE 11.18 CONNETICS DRUG DELIVERY PORTFOLIO, 2008
TABLE 11.19 CYDEX DRUG DELIVERY PIPELINE, 2008
TABLE 11.20 CARRINGTON LABORATORIES KEY FINANCIALS, 2003-2007 (US$MN)
TABLE 11.21 DEPOMED KEY FINANCIALS, 2003-2007 (US$MN)
TABLE 11.22 DEPOMED DRUG DELIVERY PORTFOLIO, 2008
TABLE 11.23 DOR BIOPHARMA KEY FINANCIALS, 2003-2007 (US$MN)
TABLE 11.24 DOR BIOPHARMA DRUG DELIVERY PORTFOLIO, 2008
TABLE 11.25 DURECT KEY FINANCIALS, 2003-2007 (US$MN)
TABLE 11.26 DURECT DRUG DELIVERY PORTFOLIO, 2008
TABLE 11.27 EMISPHERE KEY FINANCIALS, 2003-2007 (US$MN)
TABLE 11.28 EMISPHERE DRUG DELIVERY PORTFOLIO, 2008
TABLE 11.29 ENZON KEY FINANCIALS, 2003-2007 (US$MN)
TABLE 11.30 ENZON DRUG DELIVERY PORTFOLIO, 2008
TABLE 11.31 ETHYPHARM DRUG DELIVERY PORTFOLIO, 2008
TABLE 11.32 EURAND KEY FINANCIALS, 2003-2007 (US$MN)
TABLE 11.33 EURAND DRUG DELIVERY PORTFOLIO, 2008
TABLE 11.34 GENEREX KEY FINANCIALS, 2003-2007 (US$MN)
TABLE 11.35 GENEREX DRUG DELIVERY PORTFOLIO, 2008
TABLE 11.36 INOVIO KEY FINANCIALS, 2003-2007 (US$MN)
TABLE 11.37 INOVIO DRUG DELIVERY PORTFOLIO, 2008
TABLE 11.38 IVAX KEY FINANCIALS, 2003-2007 (US$MN)
TABLE 11.39 IVAX DRUG DELIVERY PORTFOLIO, 2008
TABLE 11.40 MACROCHEM KEY FINANCIALS, 2003-2007 (US$MN)
TABLE 11.41 MACROCHEM DRUG DELIVERY PORTFOLIO, 2008
TABLE 11.42 MACROMED DRUG DELIVERY PORTFOLIO, 2008
TABLE 11.43 NASTECH KEY FINANCIALS, 2003-2007 (US$MN)
TABLE 11.44 NASTECH DRUG DELIVERY PORTFOLIO, 2008
TABLE 11.45 NEKTAR KEY FINANCIALS, 2003-2007 (US$MN)
TABLE 11.46 NEKTAR DRUG DELIVERY PORTFOLIO, 2008
TABLE 11.47 NEXMED KEY FINANCIALS, 2003-2007 (US$MN)
TABLE 11.48 NEXMED DRUG DELIVERY PORTFOLIO, 2008
TABLE 11.49 NOVEN KEY FINANCIALS, 2003-2007 (US$MN)
TABLE 11.50 NOVEN DRUG DELIVERY PORTFOLIO, 2008
TABLE 11.51 PSIVIDA KEY FINANCIALS, 2003-2007 (US$MN)
TABLE 11.52 PSIVIDA DRUG DELIVERY PORTFOLIO, 2008
TABLE 11.53 PENWEST KEY FINANCIALS, 2003-2007 (US$MN)
TABLE 11.54 PENWEST DRUG DELIVERY PORTFOLIO, 2008
TABLE 11.55 PHERIN PHARMACEUTICALS DRUG DELIVERY PORTFOLIO, 2008
TABLE 11.56 QLT KEY FINANCIALS, 2003-2007 (US$MN)
TABLE 11.57 QLT DRUG DELIVERY PORTFOLIO, 2008
TABLE 11.58 SKYE PHARMA KEY FINANCIALS, 2003-2007 (US$MN)
TABLE 11.59 SKYEPHARMA DRUG DELIVERY PORTFOLIO, 2008
TABLE 11.60 WATSON KEY FINANCIALS, 2003-2007 (US$MN)
TABLE 11.61 WATSON PHARMACEUTICALS DRUG DELIVERY PORTFOLIO, 2008
TABLE 11.62 ZOGENIX PHARMACEUTICALS DRUG DELIVERY PORTFOLIO, 2008

Graphs
GRAPH 3.1 ESTIMATED DRUG DELIVERY MARKET BY MAIN GEOGRAPHIC REGIONS
GRAPH 3.2 GLOBAL SALES OF DRUG DELIVERY SYSTEMS BY KEY SEGMENTS, 2007
GRAPH 3.3 FORECAST GLOBAL SALES OF DRUG DELIVERY MARKET BY SEGMENT, US$ BILLION
GRAPH 3.4 FORECAST 2007-2012 GROWTH OF GLOBAL DRUG DELIVERY MARKET BY SEGMENT
GRAPH 4.1 TOP 5 PRODUCTS UTILIZING ORAL DELIVERY, GLOBAL SALES 2007 ($ MN)
GRAPH 4.2 LEADING ORAL DRUG DELIVERY COMPANIES, COMBINED KEY PRODUCT VALUES 2007 ($ MN)
GRAPH 4.3 KEY THERAPEUTIC AREAS OF EMPHASIS FOR ORAL DRUG DELIVERY, # OF KEY MARKETED PRODUCTS, 2007
GRAPH 4.4 TOP 5 PRODUCTS UTILIZING INHALABLE DELIVERY, GLOBAL SALES 2007 ($ MN)
GRAPH 4.5 INHALABLE DRUG DELIVERY MARKET SHARE, BY TECHNOLOGY 2007
GRAPH 4.6 TOP 5 PRODUCTS UTILIZING INJECTABLE DELIVERY, GLOBAL SALES 2007 ($ MN)
GRAPH 4.7 LEADING INJECTABLE DRUG DELIVERY COMPANIES, COMBINED KEY PRODUCT VALUES 2007 ($ MN)
GRAPH 4.8 TOP 5 PRODUCTS UTILIZING TRANSMUCOSAL DELIVERY, GLOBAL SALES 2007 ($ MN)
GRAPH 4.9 LEADING DEVELOPERS OF TRANSMUCOSAL-BASED THERAPEUTICS 2007 ($ MN)
GRAPH 4.10 LEADING TRANSDERMAL DRUG DELIVERY COMPANIES, BY # OF PRODUCTS ON MARKET
GRAPH 4.11 KEY THERAPEUTIC AREAS OF EMPHASIS FOR TRANSDERMAL DRUG DELIVERY, # OF KEY MARKETED PRODUCTS
GRAPH 5.1 LEADING COMPANIES ACTIVE IN ORAL DRUG DELIVERY DEVELOPMENT
GRAPH 5.2 LEADING INDICATIONS FOR ORAL DRUG DELIVERY PRODUCTS IN DEVELOPMENT
GRAPH 6.1 LEADING COMPANIES ACTIVE IN INHALABLE DRUG DELIVERY DEVELOPMENT
GRAPH 7.1 LEADING COMPANIES ACTIVE IN INJECTABLE DRUG DELIVERY DEVELOPMENT
GRAPH 8.1 LEADING COMPANIES ACTIVE IN INJECTABLE DRUG DELIVERY DEVELOPMENT
GRAPH 9.1 LEADING COMPANIES ACTIVE IN TRANSDERMAL DRUG DELIVERY DEVELOPMENT
GRAPH 10.1 LEADING COMPANIES ACTIVE IN NICHE/TOPICAL DRUG DELIVERY DEVELOPMENT

Figures
FIGURE 1.1 OPTIMAL TIME FOR REFORMULATION
FIGURE 1.2 GROWTH PROSPECTS IN THE DRUG DELIVERY SECTOR
FIGURE 2.1 PULSATILE DRUG RELEASE

- 3m Pharmaceuticals
- Alkermes
- Altea Therapeutics
- Alza (Johnson & Johnson)
- Aradigm
- Bioject
- Biovail
- Cardinal Health
- Cima Labs (Cephalon)
- Connetics (Stiefel Laboratories Inc)
- Cydex Pharmaceuticals
- Delsite Biotechnologies (Carrington Laboratories)
- Depomed
- Dor Biopharma
- Durect
- Emisphere
- Enzon
- Enzon
- Ethypharm
- Eurand
- Generex
- Inovio (Formerly Genetronics)
- Ivax (Part Of Teva)
- Macrochem
- Macromed (Now Protherics)
- Nastech (Now Mdrna)
- Nektar
- Nexmed
- Noven
- Penwest
- Pherin Pharmaceuticals
- Psivida
- Qlt
- Skyepharma
- Watson Pharmaceuticals
- Zogenix

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos